دوره 7، شماره 1 - ( 4-1388 )                   جلد 7 شماره 1 صفحات 0-13 | برگشت به فهرست نسخه ها

XML English Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Naderian H, Nikzad H, Aliasgharzadeh A, Atlasi M A. Polycystic ovarian patient’s serum decreases in vitro development of mouse embryo. IJRM 2009; 7 (1) :13-0
URL: http://ijrm.ssu.ac.ir/article-1-136-fa.html
Polycystic ovarian patient’s serum decreases in vitro development of mouse embryo. International Journal of Reproductive BioMedicine 1388; 7 (1) :0-13

URL: http://ijrm.ssu.ac.ir/article-1-136-fa.html


چکیده:   (2172 مشاهده)
Background: Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders which cause anovulatory infertility and hyperandrogenism in young women. The common feature in PCOS women is increased ovarian androgen secretion which can effect on the prevalence of miscarriage rate.
Objective: The aim of this study was to investigate the effect of PCOS patient's serum on in vitro developmental stages of mouse embryo from two cells to hatching blastocyst.
Materials and Methods: After superovulating and fertilizing Balb/c mice, 219 two cells embryos were retrieved, 109 embryos were cultured in 10% PCOS patient's serum and 90% medium and 110 embryos were cultured in 10% normal serum and 90% medium to hatching blastocyst stage. The PCOS patient's serum which added to medium had higher hormonal concentrations than normal serum. The early developmental stages of embryos were studied in 2, 4, 8 cells, morula, early, late and hatching blastocyst stages.
Results: The statistical analysis confirmed the decreasing rate in the number of embryos in all developmental stages from 2 cells to hatching blastocyst in PCOS group in comparison with the normal group (p<0.05).
Conclusion: The PCOS patient's serum causes the decreasing rate of in vitro development of the early stage in mouse embryos.
نوع مطالعه: Original Article |

فهرست منابع
1. Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Pérez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod 2002; 17: 2573-2579. [DOI:10.1093/humrep/17.10.2573]
2. Sheehan MT. Polycystic ovarian syndrome: diagnosis and management. Clin Med Res 2004; 2: 13-27. [DOI:10.3121/cmr.2.1.13]
3. Stein IF, Leventhal MI, Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181-191. [DOI:10.1016/S0002-9378(15)30642-6]
4. Hardy K, Robinson FM, Paraschos T, Wicks R, Franks S, Winston RM. Normal development and metabolic activity of preimplantation embryos in vitro from patients with polycystic ovaries. Hum Reprod 1995; 10: 2125-2135. [DOI:10.1093/oxfordjournals.humrep.a136247]
5. Schmid J, Kirchengast S, Vytiska-Binstorfer E, Huber J. Infertility caused by PCOS-health-related quality of life among Austrian and Moslem immigrant women in Austria. Hum Reprod 2004; 19: 2251-2257. [DOI:10.1093/humrep/deh432]
6. Homburg R. Pregnancy complications in PCOS. Best Pract Res Clin Endocrinol Metab 2006; 20: 281-292. [DOI:10.1016/j.beem.2006.03.009]
7. Hopkinson ZE, Sattar N, Fleming R, Greer IA. Polycystic ovarian syndrome: the metabolic syndrome comes to gynecology. BMJ 1998; 317: 329-332. [DOI:10.1136/bmj.317.7154.329]
8. Okon MA, Laird SM, Tuckerman EM, Li TC. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil Steril 1998; 69: 682-690. [DOI:10.1016/S0015-0282(98)00007-7]
9. Sheikha MH, Kalantar SM, Ghasemi N. Genetic of polycystic ovary syndrome. IJRM 2007; 5: 1-5.
10. Ludwig M, Finas DF, al-Hasani S, Diedrich K, Ortmann O. Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients. Hum Reprod. 1999; 14: 354-8. [DOI:10.1093/humrep/14.2.354]
11. Jabara S, Coutifaris C. In vitro fertilization in the PCOS patient: clinical considerations. Semin Reprod Med 2003; 21: 317-324. [DOI:10.1055/s-2003-43310]
12. Baravalle C, Salvetti NR, Mira GA, Pezzone N, Ortega HH. Microscopic characterization of follicular structures in letrozole-induced polycystic ovarian syndrome in the rat. Arch Med Res. 2006; 37: 830-839. [DOI:10.1016/j.arcmed.2006.04.006]
13. Mannerås L, Cajander S, Holmäng A, Seleskovic Z, Lystig T, Lönn M, Stener-Victorin E. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology. 2007; 148: 3781-3791. [DOI:10.1210/en.2007-0168]
14. Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod. 2001; 16: 2606-2609. [DOI:10.1093/humrep/16.12.2606]
15. Li MG, Ding GL, Chen XJ, Lu XP, Dong LJ, Dong MY, Yang XF, Lu XE, Huang HF. Association of serum and follicular fluid leptin concentrations with granulosa cell phosphorylated signal transducer and activator of transcription 3 expression in fertile patients with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2007; 92: 4771-4776. [DOI:10.1210/jc.2007-0978]
16. Seow KM, Juan CC, Hsu YP, Ho LT, Wang YY, Hwang JL. Serum and follicular resistin levels in women with polycystic ovarian syndrome during IVF-stimulated cycles. Hum Reprod. 2005; 20: 117-121. [DOI:10.1093/humrep/deh589]
17. Giudice LC. Endometrium in PCOS: Implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab 2006; 20: 235-244. [DOI:10.1016/j.beem.2006.03.005]
18. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19: 41-47. [DOI:10.1093/humrep/deh098]
19. Theiler K. The house mouse, atlas of embryonic development. 2nd printing, Springer-Verlag, 1989
20. Anderiesz C, Trounson AO. The effect of testosterone on the maturation and developmental capacity of murine oocytes in vitro. Hum Reprod 1995; 10: 2377-2381. [DOI:10.1093/oxfordjournals.humrep.a136302]
21. Stanczyk FZ. Diagnosis of hyperandrogenism: Biochemical criteria. Best Pract Res Clin Endocrinol Metab 2006; 20: 177-191. [DOI:10.1016/j.beem.2006.03.007]
22. Accardo C, Dattena M, Pilichi S, Mara L, Chessa B, Cappai P. Effect of recombinant human FSH and LH on in vitro maturation of sheep oocytes; embryo development and viability. Anim Reprod Sci 2004; 81: 77-86. [DOI:10.1016/j.anireprosci.2003.10.004]
23. Regan L, Owen EJ, Jacobs HS. Hypersecretion of luteinising hormone, infertility and miscarriage. Lancet 1990; 336: 1141-1144. [DOI:10.1016/0140-6736(90)92765-A]
24. Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ 1988; 297: 1024-1026. [DOI:10.1136/bmj.297.6655.1024]
25. Zhang J, Zhu G, Wang X, Xu B, Hu L. Apoptosis and expression of protein TRAIL in granulosa cells of rats with polycystic ovarian syndrome. J Huazhong Univ Sci Technolog Med Sci 2007; 27: 311-314. [DOI:10.1007/s11596-007-0324-6]
26. Cha KY, Lee DR, Cho JH, Yoon TK. In vitro maturation of immature oocytes and IVF/ICSI in PCOS patients. J Indian Med Assoc 2006; 104: 446-448.
27. Chian RC. In-vitro maturation of immature oocytes for infertile women with PCOS. Reprod Biomed Online 2004; 8: 547-552. [DOI:10.1016/S1472-6483(10)61101-7]

بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.

کلیه حقوق این وب سایت متعلق به International Journal of Reproductive BioMedicine می باشد.

طراحی و برنامه نویسی : یکتاوب افزار شرق

© 2023 CC BY-NC 4.0 | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb